Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride dissociates to provide potassium ions and chloride ions. Potassium repletion corrects hypokalemia and associated disorders.
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Oral: 40-100 mEq/day in divided doses; IV: up to 10-20 mEq/hour via central line, max 40 mEq/hour with continuous monitoring; not to exceed 200 mEq/day.
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
None Documented
None Documented
Clinical Note
moderateQuinidine + Potassium chloride
"Quinidine may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateTrimethaphan + Potassium chloride
"Trimethaphan may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateMecamylamine + Potassium chloride
"Mecamylamine may increase the ulcerogenic activities of Potassium chloride."
Clinical Note
moderateAtracurium besylate + Potassium chloride
Not applicable; potassium is an electrolyte regulated by homeostasis, not classic elimination half-life. Under normal renal function, serum half-life of administered potassium is approximately 2-4 hours due to rapid cellular uptake and renal excretion.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Primarily renal (90%) as potassium ion; minimal fecal (<10%) and sweat.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L).
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement
"Atracurium besylate may increase the ulcerogenic activities of Potassium chloride."